Meltwind

"There was an area to go and help these pharma companies do better clinical trials, and so that’s how the company started"

"When we first invested in IMU in 2024, we believed deep immune profiling combined with AI could transform precision medicine. Since then, the team has consistently delivered. The immune system sits at the heart of almost every disease, and IMU’s ability to analyse it at this resolution could redefine how treatments are matched to patients. We’re proud to be IMU’s largest shareholder and excited to support the company’s next phase of growth."

"Syndex Bio’s mcPCR platform makes amplifying DNA methylation possible for the first time. This powerful method will redefine the sensitivity and accuracy that is achievable in DNA methylation analysis, opening new possibilities for early detection and disease monitoring."

"This significant investment accelerates our lead programme in glioblastoma and follow-on programme in colorectal cancer liver metastases through the clinic, advances our pipeline in liver and lung cancers, and further enhances our Odysseus platform. We are honoured to have the support of existing and new investors who share our mission to deliver breakthrough treatments and pursue cures for the thousands of patients and families facing devastating diagnoses each year."

"Our founders have led the field by developing technology to map 3D interactions on a whole-genome scale, and integrating these data with comprehensive multi-omics datasets. We now have the technological capabilities to decipher the causal biology that drives complex and common genetic diseases, with the potential to develop truly effective new blockbuster therapies."